Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones
- Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is ongoing
- Merck initiated IND-enabling toxicology studies for the first program under the cytokine derivatives collaboration resulting in a $15 million milestone payment earned in April 2021
- EMD Serono began a Phase 1 study for the bispecific MUC1-EGFR ADC, M1231, during the first quarter of 2021
- Financial position remains strong with cash, cash equivalents and marketable securities of $294.9 million as of March 31, 2021 and projected runway into the second half of 2023
Cellectis Provides Business Update and Reports Financial Results for First Quarter 2021
Enrollment ongoing in three Cellectis-sponsored Phase 1 dose-escalation clinical studies BALLI-01 in r/r B-ALL patients, AMELI-01 in r/r AML patients and MELANI-01 in r/r MM patients in 15 US clinical centers
Five partnered allogeneic CAR-T product candidates in clinical development through our collaborations with Allogene and Servier: UCART19/ALLO-501 and ALLO-501A in r/r NHL, ALLO-715 and ALLO-605 in r/r MM and ALLO-316 in advanced or metastatic clear cell renal cell carcinoma
New collaboration with Cytovia Therapeutics, Inc. to develop TALEN
®
Successful for UCART product candidates; On track to start production of UCART product candidates in 2021
Sickle cell disease in newborns and children: What families should know and do Posted May 06, 2021, 10:30 am
Senior Faculty Editor, Harvard Health Publishing
If you’ve learned that your newborn or young child has sickle cell disease, you and other family members and friends may have many questions.
These days, most cases of sickle cell disease in the US are diagnosed through newborn screening. It’s important to make the diagnosis early, so that babies can be started on penicillin (or another antibiotic) to prevent infection. Getting connected early to a pediatrician for primary care and to specialists in blood disorders who can work closely with the child as they grow, and with their families can help prevent complications of the disease.
Researchers identify new immunotherapy treatment target for acute myeloid leukemia in children
Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in
Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children s Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML.
Leukemia is the most common cancer in children and teens, and AML accounts for nearly one-fourth of those cases. AML is a fast-growing cancer that typically starts in immature bone marrow cells.
E-Mail
ORLANDO, Fla. (May 3, 2021) - Researchers have identified a gene expressed in children with acute myeloid leukemia (AML) that could serve as a new immunotherapy treatment target, according to a new study published today in
Blood Advances, a journal of the American Society of Hematology. The study, co-authored by researchers with Nemours Children s Health System, outlines the process and potential path for new immunotherapy drugs that improve survival and reduce treatment-related toxicity in children with AML.
Leukemia is the most common cancer in children and teens, and AML accounts for nearly one-fourth of those cases. AML is a fast-growing cancer that typically starts in immature bone marrow cells.